Ocugen is trading 6.08% up at $1.13 after announcing a $40 million stock sale.
- Shares partially recovered from a 19.92% decline on September 9.
- The prior selloff followed uncertain interim Stargardt trial data.
- An independent committee recommended continuing the study under its existing protocol and collecting additional follow-up data.